Massachusetts General Hospital
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Massachusetts General Hospital sits in the top decile of US sponsors by registered trial count (#4 of 15,742 sponsors by registered trial count).
Massachusetts General Hospital: 2,032 sponsored US clinical trials, 336 recruiting.
Massachusetts General Hospital sponsors 2,032 registered US clinical trials on ClinicalTrials.gov, 336 of them currently recruiting, and 1,284 completed. 240 of these trials are in Phase 3-4 (later-stage) and 515 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 29 trials.
Top-decile sponsor footprint
Massachusetts General Hospital ranks in the top decile of sponsors by registered trial count (#4 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,284 of 1,487 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
2,032 total, page 4 of 41
School Inner City Air Study
NCT05953233
Initial Resuscitation for Acute Kidney Injury in Cirrhosis
NCT06525623
Innovating CBT-I for Cancer Survivors: An Optimization Trial
NCT06181643
Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
NCT06427954
Comparative-effectiveness of a Healthy Lifestyle and Asthma Management Program, In-person vs. ONline
NCT06432790
Modulation of Brain Oscillations Underlying Working Memory
NCT05923606
Low-Intensity Focused Ultrasound of the Amygdala for Bipolar Disorder
NCT06482762
Vagus Nerve Stimulation(VNS) As Treatment For Fibromyalgia Patients
NCT06009159
Ziftomenib Maintenance Post Allo-HCT
NCT06440135
Switching Individuals in Treatment for Opioid Use Disorder Who Smoke Cigarettes to the SREC
NCT05881304
Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma
NCT05922501
ADELANTE: A Randomized Controlled Trial to Improve Engagement in Care for Latinos With HIV
NCT06274632
A Retrospective and Prospective Natural History of Genetic Vasculopathies
NCT06552052
PET Imaging Evaluation of [11C]SY08
NCT06098612
Developing a Peer Support Intervention for Depression in SCD
NCT06358404
A Dyadic Intervention for Young Adult Patients With Cancer and Their Partner Caregivers
NCT06172907
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
NCT06302621
The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
NCT06412172
Skeletal Health and Bone Marrow Composition in Adolescents With Cystic Fibrosis
NCT06216704
Development of a Transdiagnostic Intervention for Adolescents at Risk for Serious Mental Illness
NCT05962879
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
NCT05692024
Mobile Mental Health Stigma Reduction Intervention Among Black Adults
NCT06316804
GLUCOSE-MGH: Genetic Links Understood Through Challenge With Oral Semaglutide Exposure at MGH
NCT06003153
Targeting Specific Brain Networks to Treat Specific Symptoms in Depression
NCT05523817
Elranatamab in R/R Multiple Myeloma
NCT06138275
Enhancing Modulation Effects of Baduanjin Through Neuromodulation for Knee OA
NCT05839535
Nitric Oxide Consumption as a Predictor of Vasospasm in Subarachnoid Hemorrhage
NCT07614906
Project 4: Ambulatory Biofeedback and Voice Therapy for Patients With Vocal Hyperfunction
NCT05970562
I Can Move With Purpose Now! A Pilot Lifestyle Intervention Study in Myeloproliferative Neoplasm Patients
NCT05842603
Normothermic Machine Perfusion of Steatotic Livers for Expansion of Donor Organ Pool
NCT06088758
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
NCT04875702
Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People At Risk for Alzheimer's Disease
NCT05776641
A Global Study of the PETAL Consortium
NCT06067347
Value of PET/MR Enterography in the Assessment of Crohn's Disease Using a Collagen-binding Radiotracer.
NCT06252493
Value of [68Ga]Ga-PSMA-11 PET/MRI in the Assessment of Liver Cirrhosis
NCT06265272
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
NCT05819814
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine
NCT05850091
Impact of Sex and Age on Non-visual Light Input That Affects Sleep and Circadian Rhythms
NCT05829044
Intervention for Fatigue in HCT Recipients
NCT05715047
A Randomized Clinical Trial of a Novel Drug Education and Diversion Program (iDECIDE) for Middle and High School Students
NCT06115746
Preventing Childbirth-Related PTSD With Expressive Writing
NCT05662423
NeuroPathways Intervention for Brain Tumor Patients
NCT05976490
Circuit-Based Approach to Suicide: Biomarkers, Predictors, and Novel Therapeutics
NCT04130958
Supplemental Oxygen in Pulmonary Embolism (SO-PE)
NCT05891886
Patient-centered, Optimal Integration of Survivorship and Palliative Care
NCT04900935
Cryoablation+Ipilimumab+Nivolumab in Melanoma
NCT05779423
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
NCT05914766
PET/MRI/EEG Imaging Study in Epilepsy
NCT06974305
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
NCT05998330
Sleep and Circadian Rhythm Biomarkers of Postoperative Delirium
NCT06052397
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 226 |
| Phase 2 | 289 |
| Phase 3 | 58 |
| Phase 4 | 182 |
Therapeutic Areas
What is open in the Massachusetts General Hospital pipeline
336 recruiting of 2,032 indexed (17% open); 1,284 completed (63%).
Phase mix: 240 late (III/IV) vs 515 early (I/II) (early-phase heavy).
Top condition: Depression (29 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Massachusetts General Hospital: open-pipeline peers nationwide
Peers matched on 2,032 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Massachusetts General Hospital sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 2,032 trials (± recruiting share)
- National Institute of Allergy and Infectious Diseases (NIAID) · 2,006 trials · 8% recruiting
- Memorial Sloan Kettering Cancer Center · 1,884 trials · 17% recruiting
- Pfizer · 1,845 trials · 6% recruiting
- Stanford University · 1,744 trials · 15% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Rush University Medical Center · 17% recruiting · 320 trials
- OHSU Knight Cancer Institute · 17% recruiting · 211 trials
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
Related
What to do with this Massachusetts General Hospital page
2,032 registered trials is a research-attention snapshot, not an endorsement of Massachusetts General Hospital or any single study.
- 336 of Massachusetts General Hospital's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Depression is the condition Massachusetts General Hospital studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Massachusetts General Hospital pipeline card: 2,032 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.